Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 1/20 | 0.32 |
| ▸ | CCND1 | P24385 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | SLC10A2 | Q12908 | 3/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7472192 | 0.92 | SLC10A2 (0.33) | SLC10A2MAPK10 | |
| SCHEMBL7470085 | 0.92 | SLC10A2 (0.33) | SLC10A2MAPK10 | |
| SCHEMBL17506154 | 0.91 | DRD2 (0.32) | SLC10A2 | |
| SCHEMBL17506155 | 0.91 | DRD2 (0.32) | SLC10A2 | |
| SCHEMBL2589232 | 0.84 | SLC10A2 (0.33) | SLC10A2 | |
| SCHEMBL2589094 | 0.83 | MAOA (0.37) | — | |
| SCHEMBL2585237 | 0.82 | MAPK1 (0.32) | MAPK10 | |
| SCHEMBL7469254 | 0.80 | EGFR (0.40) | SLC10A2 | |
| SCHEMBL7463854 | 0.80 | EGFR (0.40) | SLC10A2 | |
| SCHEMBL2589896 | 0.79 | MAPK1 (0.35) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834529-B2 | Synthesis of benzothiazepines | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2017-12-05 | — | — | US | disclosed |
| US-20170210717-A1 | SYNTHESIS OF BENZOTHIAZEPINES | GlaxSmithKline Intellectual Propety (No.2) Limited (GB) | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210717-A1 | SYNTHESIS OF BENZOTHIAZEPINES | GABBR1, GABRE, GABBR2 | CDK4 709/4885CCND1 1174/4885CA1 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.